Company intelligence / Profile preview

MicroLumix

Jacksonville, Florida, United Statesmicrolumix.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

MicroLumix has developed and commercialized the GermPass system, a patented light-based device that automatically kills 99.999% of harmful pathogens on high-touch surfaces within 7 seconds without chemicals. The technology is designed to reduce the spread of infectious diseases and hospital-acquired infections by disinfecting door handles, elevator buttons, restroom latches, and other common touchpoints. The company claims significant reductions in surface contamination during testing but does not report clinical trial data as it is a device/platform rather than a drug developer.

Therapeutic areas: Infectious Diseases
Modalities: Device (specifically, automated germicidal decontamination devices using light-based biotechnology)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on MicroLumix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroLumix.

Explore the full profile